The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie; Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Takeda
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Takeda
Speakers' Bureau - Celgene; Janssen
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
 
Paul G. Richardson
Consulting or Advisory Role - Celgene; Janssen; Takeda
Research Funding - Celgene; Takeda
 
Michel Attal
Research Funding - Sanofi
 
S. Vincent Rajkumar
Patents, Royalties, Other Intellectual Property - UpToDate
 
Jesus San Miguel
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; MSD; Novartis; Roche; Sanofi; Takeda
 
Meral Beksac
Consulting or Advisory Role - Amgen (Inst); Celgene (Inst); Janssen-Cilag (Inst); Takeda (Inst)
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag
 
Ivan Spicka
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Takeda
 
Xavier Leleu
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Janssen-Cilag; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Oncopeptides; Pierre Fabre; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Gilead Sciences; Janssen-Cilag; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Oncopeptides; Roche; Takeda
Travel, Accommodations, Expenses - Takeda
 
Fredrik Schjesvold
Honoraria - Abbvie; Amgen; Celgene; Janssen; Novartis; Takeda
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bayer; Bristol-Myers Squibb; Celgene; Janssen; Oncopeptides; Takeda
Research Funding - Amgen; Janssen
 
Philippe Moreau
Honoraria - Amgen; Celgene; Janssen-Cilag; Novartis; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda
 
Meletios A. Dimopoulos
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda
 
Jeffrey SY. Huang
Research Funding - Sanofi
 
Jiri Minarik
Research Funding - Sanofi
 
Michele Cavo
No Relationships to Disclose
 
H. Miles Prince
Honoraria - Amgen; Celgene; Janssen; Novartis; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda
Research Funding - Sanofi; Takeda
 
Sandrine Macé
Employment - Sanofi
 
Kathryn Penkus Corzo
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Frank Campana
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Solenn Le-Guennec
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Franck Dubin
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Kenneth Carl Anderson
Stock and Other Ownership Interests - C4 Therapeutics; OncoPep
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen Oncology; Millennium; Sanofi
Patents, Royalties, Other Intellectual Property - C4 Therapeutics; Oncopep